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Abstract
In chronic myeloid leukemia (CML), tyrosine kinase inhibitor (TKI) treatment induces autophagy that promotes survival and
TKI-resistance in leukemic stem cells (LSCs). In clinical studies hydroxychloroquine (HCQ), the only clinically approved
autophagy inhibitor, does not consistently inhibit autophagy in cancer patients, so more potent autophagy inhibitors are
needed. We generated a murine model of CML in which autophagic flux can be measured in bone marrow-located LSCs. In
parallel, we use cell division tracing, phenotyping of primary CML cells, and a robust xenotransplantation model of human
CML, to investigate the effect of Lys05, a highly potent lysosomotropic agent, and PIK-III, a selective inhibitor of VPS34,
on the survival and function of LSCs. We demonstrate that long-term haematopoietic stem cells (LT-HSCs: Lin−Sca-1+c-kit
+CD48−CD150+) isolated from leukemic mice have higher basal autophagy levels compared with non-leukemic LT-HSCs
and more mature leukemic cells. Additionally, we present that while HCQ is ineffective, Lys05-mediated autophagy
inhibition reduces LSCs quiescence and drives myeloid cell expansion. Furthermore, Lys05 and PIK-III reduced the number
of primary CML LSCs and target xenografted LSCs when used in combination with TKI treatment, providing a strong
rationale for clinical use of second generation autophagy inhibitors as a novel treatment for CML patients with LSC
persistence.
Introduction
Chronic myeloid leukemia (CML) arises following a
reciprocal chromosomal translocation within a haemato-
poietic stem cell (HSC) leading to expression of the
fusion oncoprotein BCR-ABL. Despite the significant
increase in life expectancy of CML patients due to the
development of BCR-ABL-targeting tyrosine kinase
inhibitors (TKIs) [1], a quarter of patients will fail TKI
therapy due to BCR-ABL kinase mutations, alternative
oncogene activation, or because of progression to accel-
erated phase or blast crisis [2]. Additionally, leukemic
stem cells (LSCs) are insensitive to TKIs [3, 4], giving
rise to disease persistence and reducing the possibility of
successful treatment-free remission (TFR) to only 10–
20% [5]. Although this figure may rise with second
generation TKIs, the majority of CML patients will
require lifelong TKI therapy. Therefore, a key aim is to
identify critical survival mechanisms in LSCs, such that
LSC-targeting interventions can be developed, thus
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increasing the proportion of patients that achieve sus-
tained deep molecular responses and TFR.
Autophagy is an evolutionarily conserved catabolic
process used to recycle cytoplasmic material. This process
is enabled through the formation of a double membrane
vesicle called an autophagosome, which transports cellular
material to lysosomes for degradation, and allows cells to
maintain cellular homeostasis under basal conditions and
ensure survival after exposure to stress factors [6–8].
The evidence that autophagy plays predominantly a
cytoprotective role in the context of cancer therapy has
paved the way for testing autophagy inhibition as a new
therapeutic strategy. The lysosomotropic agent hydroxy-
chloroquine (HCQ), has been shown to inhibit autophagy in
preclinical cancer models [9]. We have previously shown
that high concentration (≥10 µM) of HCQ sensitizes LSCs
to TKI treatment in vitro [10, 11]; however, concern about
the potency of HCQ in cancer patients [12–16] has pro-
moted the development of more selective and potent com-
pounds with similar chemical and lysosomotropic properties
to HCQ. Furthermore, a suitable model for visualizing and
measuring the effect of autophagy inhibitors in vivo has
been lacking and, therefore, the biological effects of
autophagy inhibition on the maintenance and function of
bone marrow (BM)-localized LSCs is currently unknown.
We previously demonstrated that the bivalent aminoqui-
noline Lys05, a dimeric analogue of chloroquine, is 3 to
10-fold more potent as an autophagy inhibitor than HCQ in
cancer cell lines [17]. Another strategy to inhibit autophagy is
targeting specific proteins involved in the formation of the
autophagosome such as the class III phosphatidylinositol
3-kinase, vacuolar protein sorting 34 (VPS34). VPS34 is
required to generate phosphatidylinositol(3)-phosphate for the
recruitment of other autophagy-related (ATG) proteins to the
nascent autophagosome membrane. Recently, selective inhi-
bitors of VPS34 kinase function have been described [18–20]
including PIK-III, which blocks de novo lipidation of the key
autophagosome component microtubule-associated protein 1
light chain 3 (LC3) and prevents cargo degradation [20].
In this study, we generated a transgenic murine model by
crossing a tetracycline-regulated CML model [21], with a
mouse bearing the autophagy marker LC3 fused to GFP
[22], which allowed accurate assessment of autophagic
vesicle accumulation in LSCs in vivo. Using this model, in
parallel with primary stem-cell enriched CML samples and
a patient-derived xenograft (PDX) model, we demonstrate
that Lys05 and PIK-III-mediated autophagy inhibition
reduces LSC quiescence and drives myeloid progenitor cell
expansion. Of clinical significance, we show that Lys05 or
PIK-III, when combined with TKIs, selectively target LSCs
providing a novel rationale to eradicate cancer stem cells in
CML patients with persistent disease.
Materials and methods
In vivo studies
Inducible Scl-tTa–BCR-ABL mice (C57Bl6 background),
Atg7flox/flox:Mx-Cre (C57Bl6/129Sv1) and GFP-LC3 (C57Bl6)
mice were generated as previously described [21–23]. For
more details, see Supplemental Methods.
Primary samples
CML samples were leukapheresis products isolated from
individuals with chronic phase CML at the time of diag-
nosis prior to TKI treatment. Non-CML samples were sur-
plus cells collected from femoral-head BM, surgically
removed from patients undergoing hip replacement or
leukapheresis products from individuals with non-myeloid
Ph− haematological disorders. CD34+ cells were isolated
using the CD34 MicroBead Kit or CliniMACS (both
Miltenyi Biotec).
Cell culture
All cultures were performed at 37 °C in a 5% CO2 incubator
(Eppendorf). For more details, see Supplemental Methods.
Stem cell and differentiation analysis in CD34+
CML cells
CD34+ CML cells were stained with 1 μM CellTrace Violet
(CellTrace Violet Cell Proliferation Kit, Life Technologies)
in PBS for 30 min at 37 °C. The reaction was quenched by
adding cell culture medium containing 10% FBS. Cells were
then washed and re-suspended in SFM supplemented with
PGF cocktail and treated as indicated in figure legends. After
3 or 6 days, cells were stained with anti-human CD34-APC
(BD Biosciences), anti-human CD38-PerCP (BioLegend)
and anti-human CD133-PE (Miltenyi Biotec). For detection
of differentiation markers, cells were stained with
anti-human CD71-PE, anti-human CD11b-PE-Cy7 and
anti-human CD14-APC-Cy7 (all from BioLegend) followed
by flow cytometry analysis (FACSVerseTM Flow Cytometer,
BD Biosciences). Data analysis was performed using
FlowJo 7.6.5 software.
Cell cycle analysis
CD34+ CML cells were fixed with 70% ethanol in PBS
following 3 days treatment with the indicated drugs (see
figure legends). Permeabilization was performed as pre-
viously described. [4] For more details, see Supplemental
Methods.
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Dual-fusion interphase fluorescence in situ
hybridization (D-FISH)
See Supplemental Methods.
In vitro treatments, CFC and LTC-IC assays
CFC and LTC-IC was performed as previously described [4].
For more details, see Supplemental Methods.
Immunofluorescence of bone sections, LC3 puncta
and RFP-GFP-LC3 detection
See Supplemental Methods.
Western blot analysis, RNA extraction and
quantitative PCR
See Supplemental Methods.
Statistics and study approval
Significance is indicated as follows: *p < 0.05; **p < 0.01;
***p < 0.001. For more details, see Supplemental Methods.
Results
Primitive CML cells have high levels of basal
autophagy in vivo
To measure basal autophagy levels in CML cells in vivo we
crossed a previously described transgenic mouse model of
CML (Scl-tTa-BCR-ABL) [21] with a mouse expressing the
autophagy marker LC3 fused to GFP [22]. After removal of
tetracycline from the drinking water, BCR-ABL expression
is induced (tet-off system) in the HSC population and mice
develop a CML-like disease, characterized by splenome-
galy, myeloid hyperplasia and a reduction in erythrocytes
and B-cells (Figure S1A-B). An increase in fluorescence in
cells expressing GFP-LC3 indicates an accumulation of
autophagic vesicles [24]. Analysis of the percentage of
GFP+ cells within different leukemic cell populations, iso-
lated from the BM of Scl-tTa-BCR-ABL/GFP-LC3 mice,
revealed that whereas only 15–20% of the cells were GFP+
in the lineage negative (Lin−) and Lin−c-kit+ (LK) popu-
lations, 85–90% of the cells in the Lin−Sca-1+c-kit+ (LSK),
multipotent progenitors (MPP) and the long-term (LT)-HSC
compartments were GFP+, reflecting a significantly higher
content of autophagosomes in primitive populations
(Fig. 1a). Similar results were obtained when the percentage
of GFP+ cells within these populations was analysed in BM
of non-leukemic mice (Figure S1C). To confirm active
autophagic flux in these primitive cells, LSK cells were
isolated from leukemic mice and cultured without cytokines
to induce autophagy. In line with previous studies per-
formed in normal haematopoietic cells, autophagy induction
was linked to increased degradation of GFP-LC3 and
therefore a reduction in GFP-LC3 levels [25], which was
reverted by HCQ-mediated autophagy inhibition (Fig-
ure S1D-F). A similar effect was observed when LC3-II
levels were measured by flow cytometry following TKI
treatment (Figure S1G). Importantly, comparison of
autophagy flux in LSK cells from leukemic and non-
leukemic mice revealed increased flux in primitive leukemic
cells compared with their normal counterparts (shown by
increase in GFP-LC3 levels following Lys05-mediated
autophagy inhibition; Figure S1H).
Lys05 inhibits autophagy in LT-HSCs in vivo and
patient-derived CML CD34+ cells
Recent Phase I studies indicate that more potent autophagy
inhibitors are required to consistently inhibit autophagy in
cancer patients [12–16]. To assess whether autophagy
inhibition can be achieved in LSCs in vivo, we treated
leukemic mice with HCQ or Lys05, followed by BM
extraction and GFP-LC3 detection in LSK cells and LT-
HSCs. Notably, HCQ treatment did not affect GFP-LC3
levels, whereas an increase in fluorescence was observed in
LSK cells and LT-HSCs purified from Lys05 treated mice,
indicating potent autophagy inhibition with the latter agent
(Figs. 1b-c). To confirm autophagy inhibition using a
separate autophagy marker, we treated leukemic mice and
quantified the accumulation of the autophagy cargo receptor
sequestosome 1 (SQSTM1/p62) in BM cells; when autop-
hagic flux is blocked, SQSTM1/p62 accumulates [24].
Immunofluorescence staining of BM sections demonstrated
that Lys05, but not HCQ treatment, produced significantly
higher levels of SQSTM1/p62 accumulation compared to
controls in leukemic cells (Figure S1I-J).
Comparing the levels of autophagy inhibition between
Lys05 and HCQ in human CML cells, K562 cells were
treated with both inhibitors at increasing concentrations.
Following 4 hours (h) treatment, a more significant increase
in membrane-bound LC3B- phosphatidylethanolamine
conjugate (LC3B-II) was observed with Lys05 at 1 µM and
10 µM concentration, indicating increased accumulation of
autophagosomes (Fig. 2a). To precisely assess autophagy
flux, we generated a K562 cell line stably expressing
fluorescence-tagged human LC3B (mRFP-GFP-LC3) that
enables different stages of autophagy to be visualized by
fluorescence microscopy [26]. The appearance of red/green
puncta (yellow when merged) indicate autophagosomes,
and as the acidic conditions in the lysosomes quench
the GFP fluorescence, “red only” puncta indicate
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autolysosomes. Autophagic flux can be inhibited by lyso-
somotropic drugs, which prevent the fusion of autophago-
somes and lysosomes, leading to build-up of yellow
fluorescence. Whereas 5 µM HCQ treatment failed to
eliminate “red only” puncta, Lys05 treatment led to a sig-
nificant accumulation of yellow fluorescence (p < 0.001),
indicating a complete block in autophagy flow (Fig. 2b).
Similar results were observed in a second human cell line—
KCL22, demonstrating that the increased potency of Lys05
is not restricted to K562 cells (Figure S2A-B).
To evaluate autophagy inhibition in patient-derived
material, we next measured autophagy inhibition
following drug treatment in stem cell-enriched (CD34+)
cells, isolated from individuals with chronic phase CML.
Since previous pharmacokinetic studies demonstrated that
the maximal achievable concentration of HCQ in plasma in
cancer patients, treated with non-toxic 800 mg/day dose, is
~2000 ng/mL (~5 µM) [12–16] we used 3–5 µM drug con-
centration of each drug in the following experiments. After
treatment with a single dose of either HCQ or Lys05,
immunofluorescence assays showed accumulation of LC3
puncta after Lys05 treatment (Figure S2C). Analysis of
additional autophagy substrates by western blot, SQSTM1/
p62, neighbour of BRCA1 gene 1 (NBR1) [27] and nuclear
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Fig. 1 Autophagy levels in LT-HSCs following in vivo treatment with
HCQ or Lys05. a Representative gating strategy used for analysis
of the different BM populations by flow cytometry (i). Percentage
of GFP+ cells in the following BM populations of leukemic mice
(n= 6); linage negative (Lin−); Lin-Sca-1-c-kit+ (LK); Lin-Sca+c-kit+
(LSK); LSK/CD48+CD150- (MPP), LSK/CD48-CD150+ (LT-HSC)
(ii). b, c Levels of GFP-LC3 in LSK (b) and LT-HSC (c i) following
in vivo treatment with vehicle (PBS), HCQ or Lys05 for 2 days (n= 4/
arm) or 7 days (n= 3/arm). Results are shown as mean fluorescence
intensity (MFI) and relative to vehicle-treated mice. Representative
histogram showing the shift in GFP-LC3 levels in LT-HSCs following
Lys05 treatment (c ii). Error bars represent ±SEM
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receptor coactivator 4 (NCOA4) [20, 28], revealed a con-
sistent increase after Lys05 treatment (Fig. 2c), confirming
that Lys05 inhibits autophagy in primary CML progenitor
cells more consistently than clinically achievable con-
centrations of HCQ.
Lys05-mediated autophagy inhibition reduces the
numbers of LSCs in vivo and in vitro
We next analysed the cellular effects on different BM
progenitor populations of leukemic mice. Intriguingly,
Lys05-treated mice showed a 50% reduction in the most
primitive LT-HSC population (p < 0.01), with no significant
effect seen in HCQ-treated mice (Fig. 3a; S3A). This
reduction in LT-HSCs was accompanied by a significant
expansion in the MPP (p < 0.01) and LSK (p < 0.001)
compartments, suggesting Lys05 targets LT-HSCs in leu-
kemic mice by promoting their maturation. In contrast, no
significant effect was seen in Lys05-treated non-leukemic
mice (Figure S3B).
As human CD34+ cells are a heterogeneous population
and genuine CML LSCs represent a small fraction of total
CD34+ cells, we have previously focused on those CD34+
cells that remain quiescent in culture [4, 29]. Therefore, we
investigated the effects of HCQ and Lys05 in more primi-
tive populations by combining assessment of CD34 and
CD133 [30] expression, with the cell division tracer Cell
Trace Violet (CTV), which allows multiplexing due to the
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Fig. 2 Autophagy levels in leukemic cells, including CD34+ cells from
CML patients, following in vitro treatment with HCQ or Lys05.
a Representative blot and quantification analysis (n= 3) showing the
levels of LC3-I/II in K652 cells following 4 h treatment with vehicle
(NDC), HCQ or Lys05 at increasing concentrations from 0.01 to
10 µM. β-tubulin was used as loading control. The ratio between
LC3-II and LC3-I was calculated with the densitometry values for each
of the conditions and normalized to the values of the correspondent
β-tubulin. Results are represented as fold change to NDC. Error bars
represent ±SEM. b Representative confocal fluorescent images of
K562 cells expressing mRFP-GFP-LC3 following 4 h treatment with
vehicle (NDC), HCQ (10 µM), Lys05 (10 µM). Quantification of
autophagosomes levels were calculated using the co-localization
coefficient between red (RFP) and green (GFP). Error bars represent
±SD. c Representative blots showing the expression levels of
SQSTM1/p62, NCOA4 and NBR1 on CD34+ cells. n= 3 individual
patient samples were assessed. Membranes were re-probed with an
anti-β-tubulin antibody as loading control
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limited spectral overlap with other fluorescent probes.
Although both compounds significantly reduced the number
of the undivided cells with high CD34 and CD133
expression (CTVmaxCD34+CD133+), the effect of 5 µM
Lys05 was more compelling, promoting a 33% reduction
after 3 days treatment (p < 0.01, Fig. 3b). Additionally, we
measured the number of cells within another well-defined
primitive population, CD34+CD38−. Although both 3 and
5 µM HCQ treatment significantly decreased the cell num-
ber (p < 0.05), treatment with equimolar concentrations of
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Fig. 3 Effects of autophagy inhibition on LSC viability. a Repre-
sentative dot plots showing the LSK, MPP and LT-HSC populations in
the BM of leukemic mice following in vivo treatment (i). Percentage
of LT-HSCs, MPPs and LSK cells in the BM of leukemic mice after
2 days of in vivo treatment with vehicle (PBS, n= 5), HCQ (n= 5) or
Lys05 (n= 5). Results are represented relative to vehicle-treated mice.
Error bars represent ±SEM (ii). b Representative plots obtained from
CellTrace Violet-stained (CTV) CD34+ CML cells cultured with
SFM+ PGF for 3 days (i). Left plot shows the number of divisions
(shown in different colours) pointing with an arrow at the undivided
fraction (CTVmax). Right plot shows the CD34+CD133+ population
gated on the undivided fraction (CTVmaxCD34+CD133+). Number of
CTVmaxCD34+CD133+ cells after 3 days of treatment with vehicle
(NDC), HCQ (5 µM) or Lys05 (5 µM). n= 4 individual patient sam-
ples (ii). (c) Total number of LSC-derived colonies measured by
LTC-IC assay of CD34+ CML cells following treatment with vehicle
(NDC), HCQ (5 µM) and Lys05 (5 µM). n= 5 individual patient
samples. Results are represented relative to NDC
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Lys05 reduced the number of CD34+CD38− cells to a
greater extent (Figure S3C). We next performed long-term
culture initiating cell (LTC-IC) assays using CD34+ cells.
This most stringent in vitro stem cell assay demonstrated
that, while HCQ had a moderate effect (p < 0.05), Lys05
treatment reduced the number of colonies by 54% (p < 0.01)
when compared to the untreated control (Fig. 3c), and by
90% following 6 days treatment (Figure S3D).
Lys05 promotes loss of quiescence and induces
maturation of human CML cells
Given our in vivo data which suggested induced maturation
of LT-HSCs following Lys05 treatment in leukemic mice
(Fig. 3a; S3A), we hypothesized that the decrease in
LTC-IC number could be explained by Lys05 driving the
LSCs out of quiescence, into a more proliferative pheno-
type. Indeed, cell cycle analysis using the proliferation
marker Ki67, combined with DNA staining using 7-AAD,
showed that the G0 fraction (Ki67low7-AADlow) was
decreased after treatment with either compound alone (p <
0.05), with 39% reduction on average observed following
Lys05 treatment (Fig. 4a). Similar results were obtained in
LSK cells isolated from leukemic mice (Figure S3E). This
correlated with an increase in colony-forming cell (CFC)
number following Lys05 treatment (Fig. 4b). To assess
whether this observation was linked to cellular differentia-
tion, we measured the expression of several mature myeloid
surface markers. Levels of the granulocyte/monocyte mar-
ker CD11b, the macrophage/neutrophil marker CD14 and
the erythroid marker CD71 were increased following
autophagy inhibition, with greater effects observed in
Fig. 4 In vitro effects of autophagy inhibition on cell cycle and dif-
ferentiation. a Representative cell density plots showing cell cycle
analysis by co-staining with Ki67/7−AAD. The percentage of quies-
cent (Ki67−) cells is highlighted in red (i). Percentage of Ki67- CD34+
CML cells following 3 days treatment with vehicle (NDC), HCQ
(3 µM) and Lys05 (3 µM) (ii). b Total number of colonies obtained
from CFCs following 3 days drug treatment of CD34+ CML cells with
vehicle (NDC), HCQ (3 µM) and Lys05 (3 µM). n= 4 patient samples.
c Levels of CD11b (i; n= 3), CD14 (ii; n= 4) and CD71 (iii, n= 4)
on CD34+ CML cells following 3 days treatment with vehicle (NDC),
HCQ (5 µM) or Lys05 (5 µM). Results are represented as percentage of
cells relative to NDC. Error bars represent ±SEM between patient
samples
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Lys05-treated cells (Fig. 4c). These data further indicate that
autophagy inhibition induces loss of quiescence and drives
LSCs into differentiation.
To demonstrate that the phenotypic effects of Lys05
treatment on leukemic mice were primarily due to autop-
hagy inhibition, we generated an autophagy deficient CML
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model by crossing the previously described Atg7flox/flox:Mx-
Cre conditional knockout mice [23] with the Scl-tTa-BCR-
ABL model. Following removal of tetracycline, mice were
injected with polyinosinic-polycytidylic acid (pIpC) to
induce a recombinase-dependent deletion of the essential
autophagy gene Atg7. As expected, a significant reduction
in Atg7 mRNA levels was achieved, which correlated with a
significant accumulation of SQSTM1/p62 staining in BM
cells, indicating an autophagy deficiency (p < 0.01, Fig-
ure S4A-C). Although the analysis of leukemic BM cells
revealed no significant difference in LT-HSCs, there was a
clear increase in the relative proportions of MPP (p < 0.001)
and LSK cells (p < 0.01) resembling the progenitor expan-
sion observed in Lys05-treated mice (Figure S4D). Similar
effects were seen in non-leukemic LT-HSCs, MPP and LSK
cells (Figure S4E). Overall, these data suggest that Lys05
achieves autophagy inhibition in LSCs and promotes dif-
ferentiation similar to genetic autophagy deficiency.
Novel autophagy inhibitors sensitize patient-
derived LSCs to TKI treatment in vitro and in vivo
To date it is unknown whether clinically achievable con-
centrations of HCQ sensitize CML LSCs to TKI treatment,
and if this combination is effective in vivo. To test the
effects of combined inhibition of autophagy and BCR-ABL
kinase activity on LSCs we first measured the number of
CTVmaxCD34+CD133+ cells after treatment with either
HCQ or Lys05 in the presence of the second generation TKI
nilotinib, which is at least 10-fold more potent than imatinib
[31]. Figure 5a shows that, whereas 5 µM HCQ in combi-
nation with nilotinib did not have any additional effects
compared to nilotinib alone, 5 µM Lys05 combined with
nilotinib showed a significant reduction in number of
CTVmaxCD34+CD133+ cells compared to the TKI alone
(p < 0.05, Fig. 5a). This additive effect was not as noticeable
in bulk CD34+ cells, indicating that the drug combination
displayed selectivity towards more primitive populations
(Figure S5A). LTC-IC assays confirmed these results,
demonstrating a reduction in LSC survival after combined
treatment with Lys05 and nilotinib, compared to TKI alone
(Fig. 5b; S5B). Real-Time quantitative PCR of individual
colonies for BCR-ABL expression confirmed the presence
of the Philadelphia (Ph) chromosome in 100% of the
colonies (Figure S5C).
To test the in vivo effect of these combinations on the
most primitive human LSCs, we used a robust PDX model
of human CML. Sub-lethally irradiated immunocompro-
mised NOD-SCID-γc−/− (NSG) mice were transplanted with
CD34+ CML cells. Twelve weeks following transplantation,
engraftment was assessed by measuring the expression of
human CD45 in peripheral leukocytes in the blood. After
ensuring equivalent and sufficient engraftment, mice were
treated daily with HCQ and Lys05 as single agents and in
combination with nilotinib (Fig. 5c). In all experimental
arms, no changes in mouse or spleen weight were
observed indicating excellent tolerability (Figure S5D-E).
Three weeks of in vivo treatment with nilotinib reduced
the absolute number of CML-derived CD45+ leukocytes
(Figure S5F) and engrafted CD45+CD34+CD38−and
CD45+CD34+CD133+ human cells within the BM
(Figs. 5d-e), but the proportion of CML-derived leukocytes
in spleen was unaffected (Figure S5G). Of clinical relevance,
while the combination of HCQ and nilotinib had modest
or no additional effect compared to nilotinib as a single
agent, Lys05 treatment enhanced the effects of the TKI by
reducing the levels of human CD45+ cells in BM and spleen
(p= 0.05 and p < 0.01 respectively, Figure S5F-G). Strik-
ingly, although the combination of Lys05 and
nilotinib were not statically different than nilotinib alone,
the combination of Lys05 and nilotinib eliminated 93% of
CD45+CD34+CD38−and 96% of CD45+CD34+CD133+
engrafted cells within the BM (Figs. 5d-e). Fluor-
escent in situ hybridization, performed on sorted human
CD45+ cells from the BM confirmed the presence of the
BCR-ABL fusion gene in over 95% of the cells
(Figure S5H).
Encouraged by our results with Lys05, we further inves-
tigated whether a more selective autophagy inhibitor could
also target LSCs when used in combination with nilotinib. To
address this we used PIK-III, a recently developed inhibitor
of the lipid kinase VPS34 [20]. Treatment with PIK-III led to
the accumulation of the autophagy substrates, NBR1,
NCOA4 and SQSTM1/p62 confirming inhibition of autop-
hagy in CD34+ CML cells (Figure S6A-B). Furthermore,
PIK-III treatment inhibited TKI-induced autophagy when
Fig. 5 Effects of combined inhibition of autophagy and BCR-ABL on
LSCs in vitro and in vivo. a Number of CTVmax CD34+ CD133+ cells
following 3 days of treatment with vehicle (NDC), nilotinib (2 µM), or
combinations of nilotinib with either HCQ (5 µM) or Lys05 (5 µM).
n= 4 patient samples. b Total number of LSC-derived colonies
measured by LTC-IC assay of CD34+ CML cells following treatment
for 3 days with vehicle (NDC), nilotinib (2 µM), or combinations of
Nil with either HCQ (5 µM) or Lys05 (5 µM). n= 5 patient samples.
Results are represented relative to NDC. Error bars represent ±SEM.
c Schematic representation showing the experimental design for
in vivo treatment of NSG mice with vehicle (n= 4), HCQ (n= 4),
Lys05 (n= 4), nilotinib (n= 4) and combinations of nilotinib with
each of the autophagy inhibitors (n= 4 for each combination).
d, e Absolute cell number of human CD45+CD34+CD38– (d), CD45
+CD34+CD133+ (e) from the BM of each mouse following 3 weeks of
in vivo treatment. f, g Absolute cell number of human CD34+CD38–
(G) and CD34+CD133+ (h) extracted from the BM of NSG mice
16 weeks post-transplant. Before transplant, CD34+ cells were treated
ex vivo for 48 h with vehicle, PIK-III (5 µM), nilotinib (2 µM) or
combination of PIK-III with nilotinib. Error bars represent ±SEM
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used in combination with nilotinib (Figure S6C). We next
examined the effect on the primitive CTVmaxCD34+CD133+
population. This revealed that 69% of CTVmaxCD34+CD133+
cells were eliminated following PIK-III alone (p < 0.01,
Figure S6D). Moreover, 90% of CTVmaxCD34+CD133+
cells were eliminated following the combination of PIK-III
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and nilotinib (p < 0.001). Since PIK-III is not suitable for
in vivo treatment [20], to examine the effect on engraftment
of primitive LSCs, CD34+ CML cells were treated for 48 h
with PIK-III, nilotinib or the combination, and transplanted
into NSG mice with the engraftment of human Ph+ cells
measured after 16 weeks. In agreement with our previous
work, in vitro TKI treatment leads to enrichment of primi-
tive cells [4, 29, 32]. The reduction in engrafted CD45
+CD34+ CML cells following single PIK-III treatment,
including primitive CD45+CD34+CD38−and CD45+CD34
+CD133+ populations, confirmed the essential role of
autophagy in the maintenance of the LSC pool (Figs. 5f-g;
S6E). Importantly, comparison of the combination treat-
ment with single TKI treatment revealed a decrease in the
number of CML LSCs in the combination arm, further
confirming the importance of autophagy in TKI-treated
quiescent LSCs.
To test the effect of second generation autophagy inhi-
bitors on normal blood cells, CD34+ cells derived from
separate donors were treated with HCQ, Lys05 or the
combination of PIK-III and nilotinib, and compared with
the cytotoxicity of 20 nM bortezomib and 10 nM omace-
taxine treatment. This revealed that while bortezomib and
omacetaxine substantially affected the CFC potential of
normal progenitor cells, the effect of Lys05 and PIK-III-
mediated autophagy inhibition had only minimal effect
(Figure S6F-G). Since neither Lys05 nor PIK-III promoted
an increase in the number of CFCs, our results also sug-
gested that the myeloid expansion seen following
autophagy inhibition in CML cells (Figs. 4b-c) was selec-
tive for Ph+ cells.
Combination of TKI and Lys05 eliminates
transplantable LT-HSCs
To further study the selectivity and the functional effect of
combining Lys05 with TKI on transplantable LSCs in vivo,
we used the Scl-tTa-BCR-ABL model, which allows dis-
crimination of host and donor cells in a transplantation
setting using the CD45.1/45.2 system. First, we transplanted
BM cells from CD45.2 Scl-tTa–BCR-ABL donor mice into
sub-lethally irradiated CD45.1 wild type (WT) recipients
(n= 18). Following tetracycline removal, induction of
BCR-ABL expression and evidence of CML-like disease,
four cohorts of mice were treated with vehicle, Lys05,
nilotinib or the combination for three weeks (Fig. 6a). As
expected, although the vast majority of the cells in the BM
were of donor origin (CD45.2) (Fig. 6b), the leukemic
burden was reduced in nilotinib-treated mice, evidenced
by reduction in splenomegaly and absolute numbers of
CD45.2+ donor cells in the spleen (Fig. 6c; S7A). As pre-
viously reported, relatively low numbers of transplanted
LT-HSCs were visible in the host BM of leukemic mice due
to the rapid differentiation induced by BCR-ABL expres-
sion [33] (Fig. 6d). Whereas the anti-proliferative effect of
nilotinib resulted in a significant accumulation of CD45.2
LT-HSCs in treated recipient mice (p < 0.01), the combi-
nation with Lys05 treatment reduced this effect by 69% (p
< 0.05), mirroring the efficacy of PIK-III in eliminating
LSCs when combined with TKI treatment in the xenograft
model (compare Figs. 5f-g with 6Dii). Single colony PCR
confirmed BCR-ABL expression in surviving CD45.2 LSK
cells (Figure S7B). To assess whether the surviving cells
possessed repopulation potential, BM cells from each
separate cohort were pooled and 3 × 106 cells transplanted
into secondary CD45.1 WT recipients. Following 6 weeks
of disease development, analysis of the chimerism between
CD45.1 and CD45.2 cells in the BM of secondary recipients
was assessed. This revealed that mice transplanted with BM
cells from vehicle and Lys05 treated mice showed
similar CD45.1/CD45.2 ratio for vehicle (54 ± 15/55 ± 15)
and for Lys05 (40 ± 16/54 ± 17), whereas BM from the
nilotinib treated mice repopulated the secondary
recipients almost exclusively with CD45.2 cells (Fig. 6e).
This was in line with the increased number of LT-HSCs
in nilotinib treated primary recipients (Fig. 6). Strikingly, 4
out of 6 mice receiving BM from the combination
cohort had a higher ratio of CD45.1 non−leukemic cells
in BM of secondary recipients, indicating that the addition
of Lys05 to nilotinib selectively targeted leukemic
cells with repopulation capacity over normal LT-HSCs
(Fig. 6e).
Fig. 6 Targeting repopulating cells in Scl-tTa-BCR-ABL mice by
combining Lys05 with nilotinib. a Schematic diagram of the experi-
mental design. BM cells obtained from Scl-tTa-BCR-ABL CD45.2
mice were transplanted (2 × 106cells/mouse) into WT CD45.1 sub-
lethally irradiated recipients (2 × 4.25 Gy, 3 h a part). 3 weeks post-
transplant, tetracycline was removed and after 4 weeks, the mice were
randomly separated in 4 experimental arms as indicated. Mice were
treated for 21 days with vehicle (n= 4); Lys05 (n= 5), nilotinib
(n= 5) or combination of Lys05 and nilotinib (n= 4) followed by
analysis of the BM and spleens. BM cells were transplanted into new
CD45.1 WT recipients (3 × 106 cells/mouse) and the mice were left off
tetracycline for 6 weeks before analysis of the BM. b CD45.1 and
CD45.2 cells shown as percentage of total BM cells in primary reci-
pients following 21 days of in vivo treatment with vehicles (n= 4);
Lys05 (n= 5), nilotinib (n= 5) or combination of Lys05 and nilotinib
(n= 4). c Representative photograph of the spleens collected from
primary transplanted mice after the treatment (i). Mouse spleen weight
from each experimental arm (ii). d Representative plots showing the
percentage of CD45.2+ LT-HSCs in the BM of treated mice (i).
Absolute number of CD45.2+ LT-HSCs in the BM of leukemic mice
following 21 days of treatment (ii). e Representative plots showing the
percentage of CD45.1 and CD45.2 cells in the BM of secondary
recipients 6 weeks post-transplant (i). Percentage of CD45.1 and
CD45.2 cells in BM of secondary recipients from all experimental
arms (vehicle, n= 5; Lys05, n= 5; nilotinib, n= 6; combination of
Lys05 and nilotinib, n= 6) measured at week 6 post-transplant (ii).
Error bars represent ±SEM
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Discussion
Although studies have described a role for autophagy in
normal haematopoiesis [25, 34–36], the consequences of
modulating this process in a leukemic microenvironment is
currently unknown. Here, using in vivo CML models, we
show for the first time that primitive leukemic cells have
higher autophagy levels than more differentiated cells. This
observation highlights the importance of studying the
effects of autophagy inhibition in the most clinically rele-
vant population, known to be resistant to the standard of
care for CML patients.
We use a double transgenic model of CML, where
BCR-ABL expression is induced in stem cells [21], and
demonstrate that Lys05 treatment consistently inhibits
autophagy in CML LSCs in vivo, while HCQ approx-
imating clinically achievable concentrations fails to do so.
In terms of molarity, the dose of HCQ used in vivo (32
mg/kg/day; 73.74 nmols/g), corresponds to double the
concentration of Lys05 used (20 mg/kg/day; 36.37 nmols/
g), which is lower than the Lys05 dosage used in previous
studies [17, 37], underlining the improved potency of
Lys05 in inhibiting autophagy in LSCs in vivo. Interest-
ingly, we found that an active autophagic flux is essential
for the maintenance of undifferentiated quiescent LSCs,
since potent autophagy inhibition with Lys05 led to a
rapid reduction of LT-HSCs in vivo, followed by an
increase in progenitor cells (represented by the MPP and
LSK compartments). These results are in line with our
in vitro experiments using CD34+ cells derived from
CML patients, where Lys05 treatment decreases the
number of LTC-ICs and increases the CFCs derived from
progenitor cells. Notably, these effects were either absent
or lower following in vivo or in vitro treatment with HCQ
at clinical achievable concentrations.
In terms of the role autophagy plays in preventing
maturation of haematopoietic cells, our findings are in
agreement with results obtained by Ho and colleagues,
which showed that genetic inhibition of autophagy by
ATG12 deletion leads to an expansion of myeloid pro-
genitor cells [34]. In addition, conditional deletion of ATG7
or FIP200 in the haematopoietic system triggers myeloid
differentiation and expansion of LSK cells, followed by a
reduction of fetal HSCs [35] or HSCs from young (7-week-
old) mice [36]. In our work, we generated a double indu-
cible system, which allowed simultaneous ATG7 deletion
and BCR-ABL induction in adult HSCs. When comparing
autophagy deficient leukemic (and non-leukemic) mice with
autophagy competent mice, leukemic ATG7−/− mice
showed an expansion of the LSK fraction (which was
similar to Lys05-treated leukemic mice), although no sig-
nificant differences in LT-HSCs were observed between the
two phenotypes. This could be explained by the rapid
development of leukemia we observed in ATG7+/+ com-
pared to ATG7−/− mice; due to the differentiation of LT-
HSCs following BCR-ABL expression previously reported
in this model [38], a more advanced stage of disease in the
autophagy competent mice would mask the decrease of LT-
HSCs following ATG7 deletion. Further studies are
required to assess the role of autophagy in different stages
of the disease and to delineate cell type specific responses to
autophagy inhibition, which will lead to deeper under-
standing of the biological implications of autophagy in
leukemia development and progression. In this regard, the
status of p53 should be considered, since several reports
have indicated that the tumour suppressor is essential for the
role autophagy plays in tumour initiation and progression in
other types of cancer [39, 40]. Nevertheless, the expansion
of progenitor cells observed in our model, reinforced by
results in normal haematopoiesis, strongly support that the
Lys05-mediated effect in LSCs is due to autophagy
inhibition.
A possible mechanism for the differentiation of primitive
cells following Lys05 treatment is an increase in
mitochondria-derived reactive oxygen species (ROS). We
and others have previously linked autophagy deficiency in
leukemic cells with an increase in mitochondria content and
elevated oxidative phosphorylation [11, 34]. It is possible
that the increase in oxidative phosphorylation could lead to
ROS leakage from the electron transport chain. In fact,
increased ROS caused by deletion of FoxO, a transcrip-
tional factor that regulates the expression of antioxidant
proteins, leads to a myeloid expansion [41], resembling the
increase in myeloid progenitor cells we observed following
in vivo treatment with Lys05.
Recent Phase I dose-escalation clinical trials, where
maximum tolerated dose and safety of HCQ was eval-
uated, have indicated that autophagy inhibition remains a
promising strategy for improving the efficacy of cancer
therapy. However, these studies also revealed that dose-
limiting toxicity prevents escalation to a high enough dose
of HCQ to reach 10 µM concentration in plasma [12–16].
Therefore, HCQ-mediated autophagy inhibition is not
consistently achieved in cancer patients, emphasizing the
need to investigate more potent second generation
autophagy inhibitors in robust pre-clinical models. Both
in vitro studies and the robust PDX model showed that
Lys05 and PIK-III, but not HCQ, enhance the effects of
TKI on the most primitive cells. Additionally we
demonstrate that the combination of Lys05 and nilotinib
can eliminate cells that are able to regenerate transplan-
table disease, while the treatment with TKI as single agent
enriched for these cells. This is critical since LT-HSCs
have shown heterogeneity in leukemia-initiating capacity,
suggesting that only a sub-fraction of long-term engraft-
ing cells has LSC capacity [42].
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Finally, CD34+ normal cells were only modestly affected
by treatment with PIK-III or Lys05 compared to CD34+
CML cells, suggesting a potential therapeutic window for
autophagy inhibition as a CML therapy. Therefore, given
that the presence of LSCs after TKI treatment has been
associated with disease relapse [43], our results provide a
strong rationale for considering second generation autop-
hagy inhibitors as a potential clinical option for CML
patients with minimal residual disease.
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